Prognosis of unresectable hepatocellular carcinoma: Comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a chinese cohort

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Zhang, Jin Feng ^a   Shu, Zhi Jun ^a   Xie, Chun Yi ^a   Li, Qi ^b   Jin, Xi Hong ^c   Gu, Wei ^d   Jiang, Fang Jian ^a   Ling, Chang Quan ^d  

^a Shanghai Traditional Chinese Medicine Integrated Hospital   (China)

^b SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; SODIUM;

ADULT; AGED; ARTICLE; CANCER OF THE LIVER ITALIAN PROGRAM; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINA INTEGRATED SCORE; CHINESE; CHINESE UNIVERSITY PROGNOSTIC INDEX; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; INTERMETHOD COMPARISON; JAPAN INTEGRATED STAGING; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OKUDA BARCELONA CLINIC LIVER CANCER; OVERALL SURVIVAL; PORTAL VEIN; SODIUM BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; VERY ELDERLY; CARCINOMA, HEPATOCELLULAR; CHINA; COMPLICATION; HEPATITIS B; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHINA; FEMALE; HEPATITIS B; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; YOUNG ADULT;

EID: 84897514295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088182     Document Type: Article

References (29)

1. Lei HJ, Chau GY, Lui WY, Tsay SH, King KL, et al. (2006) Prognostic value and clinical relevance of the 6th Edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. J Am Coll Surg 203: 426-435.
2. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928. (Pubitemid 15228292)
3. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338.
4. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755.
5. (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31: 840-845.
6. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, et al. (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94: 1760-1769. (Pubitemid 34241115)
7. Chan SL, Mo FK, Johnson PJ, Liem GS, Chan TC, et al. (2011) Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J Gastroenterol Hepatol 26: 340-347.
8. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: 207-215. (Pubitemid 36527122)
9. Kudo M, Chung H, Haji S, Osaki Y, Oka H, et al. (2004) Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 40: 1396-1405. (Pubitemid 39657014)
10. Zhang BH, Wang XH, Yue HY, Ling CQ (2010) A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma. J Cancer Res Clin Oncol 136.
11. Cho YK, Chung JW, Kim JK, Ahn YS, Kim MY, et al. (2008) Comparison of 7 staging systems for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Cancer 112: 352-361.
12. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, et al. (2010) Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models. Cancer 116: 9.
13. Collette S, Bonnetain F, Paoletti X, Doffoel M, Bouche O, et al. (2008) Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol 19: 1117-1126. (Pubitemid 351796337)
14. Huitzil-Melendez FD, Capanu M, O'Reilly EM, Duffy A, Gansukh B, et al. (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28: 6.
15. Op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, et al. (2012) Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One 7: e45066.
16. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, et al. (2005) Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41: 707-716. (Pubitemid 40462931)
17. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, et al. (2005) Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 100: 1764-1771. (Pubitemid 41648432)
18. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, et al. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35: 421-430. (Pubitemid 32844200)
19. Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, et al. (2012) Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol 4: 256-261.
20. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, et al. (2012) Defining the severity of liver dysfunction in patients with hepatocellular carcinoma by the model for end-stage liver disease-derived systems. Dig Liver Dis 44: 868-874.
21. Huo TI, Lin HC, Hsia CY, Huang YH, Wu JC, et al. (2008) The MELD-Na is an independent short-and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey. Dig Liver Dis 40: 8.
22. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q (2013) Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 12: 6873.
23. Kondo K, Chijiiwa K, Kai M, Otani K, Nagaike K, et al. (2009) Surgical strategy for hepatocellular carcinoma patients with portal vein tumor thrombus based on prognostic factors. J Gastrointest Surg 13: 1078-1083.
24. Sun HC, Zhuang PY, Qin LX, Ye QH, Wang L, et al. (2007) Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 96: 37-45. (Pubitemid 47015447)
25. Xiaohong S, Huikai L, Feng W, Ti Z, Yunlong C, et al. (2010) Clinical significance of lymph node metastasis in patients undergoing partial hepatec-tomy for hepatocellular carcinoma. World J Surg 34: 1028-1033.
26. Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, et al. (2007) Clinical features and prognosis of patients with extrahepatic metastases from hepatocel-lular carcinoma. World J Gastroenterol 13: 414-420. (Pubitemid 46178976)
27. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
28. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, et al. (2006) Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 44: 723-731.
29. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, et al. (2005) Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 54: 411-418. (Pubitemid 40299100)